Veteran biotech investment group Circadian Technologies (ASX:CIR) has posted an AUD$21.77 million profit before tax for the 2004/05 financial year, up from $5.8 million for the previous corresponding year.

Ruth Beran discovers how one of Australia's great bioentrepreneurs has moved from inspiring shareholders to inspiring a nation.

Australian Biotechnology News journalist Ruth Beran asked Axon Instruments founder Alan Finkel if he had any advice for Australian companies with an eye on the world stage. Here is his reply.

Bioscience entrepreneurs, including Axon Instruments founder Alan Finkel and Fiona Wood and Marie Stoner of Clinical Cell Culture, have dominated the winners' circle at this year's ATSE Clunies Ross Awards.

Circadian Technologies (ASX:CIR) has posted a AUD$5.8 million profit for the 2003-04 financial year, and the prospects of an even better year next year thanks to the recent acquisition of its investee company Axon Instruments by US firm Molecular Devices on July 1.

Ask Alan Finkel what he would do differently if he started another company, and he’s quick to reply. “I wouldn’t start another company overseas,” he says.

Since last year's BIO, the Australian biotechnology sector has been all about growth, writes Melissa Trudinger.

Biosignal (ASX:BOS) listed today on the Australian Stock Exchange, with shares leaping to AUD$0.38, a premium of almost 100 per cent on its $0.20 issue price.

Microarray and cellular screening company Axon Instruments (ASX:AXN) has accepted a friendly takeover offer from California-based Molecular Diagnostics.